原发性腹膜癌的药物治疗进展
Progress in Chemotherapy for Primary Peritoneal Cancer
摘要
原发性腹膜癌患者的病理特征与卵巢浆液性乳头状癌相似,临床表现酷似晚期卵巢癌。98%的患者就诊时已为Ⅲ或Ⅳ期,以肿瘤细胞减灭术为主,术后予适当化学治疗。文章主要就原发性腹膜癌药物治疗进展作一综述。
出处
《中国肿瘤》
CAS
2008年第11期950-953,共4页
China Cancer
参考文献22
-
1Bloss JD, Liao SY, Buller RE, et al. Extraovarian peritoneal serous papillary carcinoma: a case-control retrospective comparison to papillary adeno carcinoma of the ovary[J]. Gynecol Oncol, 1993, 50(3):347-351.
-
2Bloss JD, Brady MK, Liao SY, et al. Extraovarian peritoneal serous papillary carcinoma: a phase Ⅱ trial of cisplatin and cyclophosphamide with comparison to a cohort with papillary serous ovarian carcinoma: a Gynecologic Oneology Group Study[J]. Gynecol Oneol, 2003, 89(1): 148-154.
-
3Vasey PA, Jayson GC, Gordon A, et al. Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma [J]. J Natl Cancer Inst, 2004, 96(22):1682.
-
4Escobar PF, Markman M, Rose P, et al. Phase 2 trial of carboplatin, paclitaxel, and irinotecan in ovarian, fallopian tube, and primary peritoneal cancers[J]. Gynecol Oncol, 2004, 92(1):192-196.
-
5Alberts DS,Marth C, Alvarez RD, et al. Randomized phase 3 trial of interferon gamma-lb plus standard carboplatin/ paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: Results from a prospectively designed analysis of progression-free survival[J]. Gynecol Oncol, 2008, 109(2): 174-181.
-
6Tangjitgamol S, See HT, Manusirivithaya S, et al. Thirdline chemotherapy in platinum and paclitaxel-resistant ovarian, fallopian tube, and primary peritoneal carcinoma patients[J]. Int J Gynecol Cancer, 2004, 14(5):804- 814.
-
7Bourke DC, Levenback C, Wolf JK, et al. Phase Ⅱ trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer[J]. J Clin Oncol, 2003, 21(2): 291-297.
-
8Miller DS, Blessing JA, Waggoner S, et al. Phase Ⅱ evaluation of 9-aminocamptothecin (9-AC,NSC#603071) in platinum-resistant ovarian and primary peritoneal carcinoma:a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2005, 96(1):67-71.
-
9Strauss HG, Hemsen A, Karbe I, et al. Phase Ⅱ trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer[J]. Anticancer Drugs, 2008, 19(5):541-545.
-
10Sood AK, Lush R, Geisler JP, et al. Sequential intraperitoneal topotecan and oral etoposide chemotherapy in recurrent platinum resistant ovarian carcinoma: results of a phase Ⅱ trial[J]. Clin Cancer Res, 2004, 10(18):6080- 6085.
二级参考文献20
-
1Dredge K, Horsfall R. Robinson SP. et al. Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro.Microvasc Res, 2005, 69(1-2):56-63.
-
2Geitz H, Handt S. Zwingenberger K,et al. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology, 1996, 31(2 3):213-221
-
3Gupta D. Treon SP. Hidehima T, et al. Adherence of muhiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion:therapeutic applications.Leukemia, 2001, 15(12)41950-1961.
-
4Richardson P. Schlossman R. Anderson K. al,Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed muhiple myeloma, Blood.2002, 100(9):3063-3067.
-
5Nicholas M, Constantine S, Mitsiades, et al. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood, 2002, 99(12):4525-4530.
-
6Chauhan D, Li G, Hideshima T, et al. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in muhiple myeloma(MM) cells. J Biol Chem, 2003, 278(20):17593-17596.
-
7Davies FE, Raje N, Hideshima T, et al. Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicityin multiple myeloma. Blood, 2001, 98(1):210-216.
-
8Martin J, Andrea P, Ann-Marl F, et al. Lenalidomide Selectively Inhibits In Vitro Growth of the Malignant Clone in Myelodysplastic Syndrome (MDS) Patients with 5q Deletion. Blood, 9005, 106:960a.
-
9Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 2000. 96(9) :2943-2950.
-
10List AF. Kurtin S, Roe DJ,et al. Efficacy of Lenalidomide in Myelodysplastic Syndromes. N Engl J Med, 2005. 352 (6):549-557.
共引文献6
-
1陈华,陈文俊.原发性腹膜癌治疗进展[J].实用医学杂志,2007,23(23):3648-3650.
-
2肖志坚.骨髓增生异常综合征的临床关注的若干问题[J].医学新知,2008,18(3):125-128. 被引量：4
-
3叶海格,梁彬,钱红兰,毕来喜,沈志坚,俞康.雷利度胺单用或联合用药治疗多发性骨髓瘤[J].实用肿瘤杂志,2008,23(6):565-567. 被引量：3
-
4程迎秋,张石革.抗肿瘤药的进展与临床评价——肿瘤治疗合理用药专家圆桌会议纪要[J].中国医院用药评价与分析,2009,9(1):1-3.
-
5黄春晖.沙利度胺联合CHOP方案治疗弥漫大B细胞淋巴瘤临床研究[J].中华临床医师杂志（电子版）,2016,10(5):741-743. 被引量：6
-
6夏恒志,杨艳敏,李一丹,郝秀君,王佩,董照,原现华.丙戊酸钠和沙利度胺联合化疗治疗T细胞淋巴瘤疗效观察[J].河北医药,2017,39(11):1694-1696. 被引量：2
-
1吴文成.垂体瘤的药物治疗进展[J].国外医学（内分泌学分册）,1990,10(2):72-75.
-
2王晖,刘心.多发性骨髓瘤的发病机制及药物治疗进展[J].国际病理科学与临床杂志,2006,26(5):403-406. 被引量：6
-
3黄健(综述),王晓稼(审校).晚期乳腺癌分子靶向药物治疗进展[J].国际肿瘤学杂志,2008,35(3):189-192.
-
4罗思红.慢性髓细胞白血病的药物治疗进展[J].北方药学,2013,10(8):49-49.
-
5张庆利.化疗所致胃肠道反应的药物治疗进展[J].中国社区医师,2002,18(8):8-8.
-
6闫志华.乳腺癌的药物治疗进展[J].山西医药杂志,2007,36(8):720-722.
-
7黄镜.晚期食管癌的药物治疗进展[J].中国临床研究,2010,23(1):1-4. 被引量：7
-
8王兵(综述),于甬华(审校).胆道系统癌药物治疗进展[J].国际肿瘤学杂志,2009,36(8):619-621.
-
9贾臻,胡夕春.乳腺癌的药物治疗进展[J].世界临床药物,2011,32(8):511-512. 被引量：3
-
10龚新雷,秦叔逵.胰腺癌的药物治疗进展[J].临床肿瘤学杂志,2007,12(1):68-76. 被引量：8
